During the third quarter, Cantor Fitzgerald Investment Advisors L.P. established a new position in Elevance Health by acquiring 4,510 shares valued at approximately $1.46 million. This move underscores growing confidence among major asset managers, joining other institutions such as Vermillion & White Wealth Management Group (which nearly doubled its position to 76 shares) and BOK Financial Private Wealth (a new stake of roughly $32,000). Overall, hedge funds and institutional investors now account for 89.24% of shares outstanding, reflecting a concentrated ownership base poised to influence governance and strategic decisions.

Elevation Health’s research coverage spans 24 analysts, with 12 assigning a Buy recommendation, 11 a Hold and one a Sell. Recent reports show mixed adjustments: UBS trimmed its target modestly and reiterated a Buy, while Barclays lowered its view to Overweight after revising assumptions on care-cost trends. Guggenheim bucked the trend with an upgrade, citing improving utilization metrics, and Deutsche Bank maintained a Hold stance despite tempering near-term margin forecasts. The current consensus indicates tempered upside potential compared to earlier in the year.

In its October quarterly release, Elevance Health reported adjusted earnings per share of $6.03, surpassing consensus estimates by $1.00, and delivered revenue of $50.09 billion, beating forecasts by nearly $830 million and representing 12% year-over-year growth. Net margin stood at 2.84%, while return on equity reached 16.17%. The company also declared a quarterly dividend of $1.71 per share, translating to an annualized yield of approximately 2.0% and a payout ratio below 28%, signaling capacity to sustain distributions alongside reinvestment in care-innovation initiatives.

Elevance Health maintains a conservative balance sheet, with a debt-to-equity ratio of 0.71 and both quick and current ratios at 1.56, ensuring ample liquidity to navigate reimbursement cycles. Market capitalization sits near $78 billion, supported by a price-to-earnings multiple of 14.3 and a price/earnings-to-growth ratio of 1.61. A beta of 0.52 further highlights the stock’s lower volatility relative to the broader market, suggesting downside protection during periods of elevated sector uncertainty.